| Literature DB >> 36061143 |
E Kontsek1, A Pesti1, J Slezsák2, P Gordon3, T Tornóczki4, G Smuk4, S Gergely2, A Kiss1.
Abstract
Introduction: Lung cancer is the most common malignancy worldwide. Squamous cell carcinoma (SQ) and adenocarcinoma (LUAD) are the two most frequent histological subtypes. Small cell carcinoma (SCLC) subtype has the worst prognosis. Differential diagnosis is essential for proper oncological treatment. Life science associated mid- and near-infrared based microscopic techniques have been developed exponentially, especially in the past decade. Vibrational spectroscopy is a potential non-destructive approach to investigate malignancies. Aims: Our goal was to differentiate lung cancer subtypes by their label-free mid-infrared spectra using supervised multivariate analyses. Material andEntities:
Keywords: FTIR; LDA; SVM; fingerprint region; infrared; lung cancer; transflectance
Mesh:
Year: 2022 PMID: 36061143 PMCID: PMC9428038 DOI: 10.3389/pore.2022.1610439
Source DB: PubMed Journal: Pathol Oncol Res ISSN: 1219-4956 Impact factor: 2.874
FIGURE 1Representative H&E stained region of a LUAD and multicolor average absorbance infrared image overlayed over the identical area (on the left). Representative spectrum (4000-650 cm−1) of LUAD of the location marked with a star (on the right).
Clinicopathological features of the patients.
| Case | Subtype | Age | Sex | Specimen type | Stage |
|---|---|---|---|---|---|
| 1 | SQ | 54 | Male | Resection | T2bNxMx |
| 2 | LUAD | 48 | Male | Resection | T2aNxMx |
| 3 | SQ | 59 | Male | Biopsy | Not applicable |
| 4 | SQ | 67 | Male | Biopsy | Not applicable |
| 5 | LUAD | 57 | Male | Resection | Not applicable |
| 6 | LUAD | 48 | Male | Resection | T3NxMx |
| 7 | SCLC | 59 | Male | Biopsy | T2N2M1 |
| 8 | SQ | 66 | Female | Biopsy | T3N1M0 |
| 9 | SCLC | 51 | Male | Resection | T2aN0Mx |
| 10 | SCLC | 65 | Male | Biopsy | T4N1M1 |
| 11 | SQ | 68 | Male | Resection | T2aN0M0 |
| 12 | SCLC | 71 | Male | Biopsy | T4N2M1 |
| 13 | SQ | 75 | Male | Resection | T2bN0M0 |
| 14 | SCLC | 59 | Female | Biopsy | T4N2M1b |
| 15 | LUAD | 65 | Female | Biopsy | T4N3Mx |
| 16 | SCLC | 72 | Female | Biopsy | T3N1Mx |
| 17 | LUAD | 79 | Female | Resection | T1aNxMx |
| 18 | SQ | 65 | Male | Biopsy | T3N0M0 |
| 19 | SQ | 60 | Male | Resection | T1bNxMx |
| 20 | LUAD | 78 | Female | Resection | T2aNxMx |
| 21 | LUAD | 63 | Male | Resection | T1cN0Mx |
| 22 | LUAD | 63 | Female | Resection | T2aN2Mx |
| 23 | SCLC | 57 | Female | Resection | T2aN0Mx |
| 24 | LUAD | 65 | Female | Biopsy | TaN3M1c |
| 25 | SCLC | 52 | Male | Biopsy | T4N3M0 |
| 26 | SCLC | 64 | Female | Biopsy | Not applicable |
| 27 | SCLC | 69 | Female | Biopsy | Not applicable |
| 28 | SQ | 67 | Male | Resection | T2bN0Mx |
| 29 | SQ | 71 | Male | Resection | T2aN0Mx |
| 30 | LUAD | 58 | Male | Resection | T2aNxMx |
FIGURE 2The scheme of experimental setup.
Accuracy of the prediction models using different cut-off values.
| Models cut-off | Linear nu-SVC SVM | Linear C-SVC SVM | Linear LDA | Quadratic LDA | Mahalanobis LDA |
|---|---|---|---|---|---|
| 50% | |||||
| SQ | 90% (9/10) | 100% (10/10) | 70% (7/10) | 100% (10/10) | 0% (0/10) |
| SCLC | 90% (9/10) | 100% (10/10) | 50% (5/10) | 80% (8/10) | 0% (0/10) |
| LUAD | 10% (1/10) | 100% (10/10) | 20% (2/10) | 20% (2/10) | 100% (10/10) |
| 60% | |||||
| SQ | 80% (8/10) | 80% (8/10) | 60% (6/10) | 100% (10/10) | 0% (0/10) |
| SCLC | 90% (9/10) | 90% (9/10) | 40% (4/10) | 70% (7/10) | 0% (0/10) |
| LUAD | 0% (0/10) | 80% (8/10) | 20% (1/10) | 20% (2/10) | 100% (10/10) |
| 70% | |||||
| SQ | 50% (5/10) | 80% (8/10) | 50% (5/10) | 90% (9/10) | 0% (0/10) |
| SCLC | 90% (9/10) | 90% (9/10) | 40% (4/10) | 60% (6/10) | 0% (0/10) |
| LUAD | 0% (0/10) | 70% (7/10) | 20% (2/10) | 20% (2/10) | 100% (10/10) |
| 80% | |||||
| SQ | 20% (2/10) | 70% (7/10) | 50% (5/10) | 90% (9/10) | 0% (0/10) |
| SCLC | 80% (8/10) | 80% (8/10) | 40% (4/10) | 50% (5/10) | 0% (0/10) |
| LUAD | 0% (0/10) | 60% (6/10) | 20% (2/10) | 20% (2/10) | 100% (10/10) |
| 90% | |||||
| SQ | 10% (1/10) | 20% (2/10) | 40% (4/10) | 70% (7/10) | 0% (0/10) |
| SCLC | 40% (4/10) | 70% (7/10) | 40% (4/10) | 30% (3/10) | 0% (0/10) |
| LUAD | 0% (0/10) | 60% (6/10) | 20% (2/10) | 20% (2/10) | 100% (10/10) |
| 95% | |||||
| SQ | 0% (0/10) | 20% (2/10) | 40% (4/10) | 30% (3/10) | 0% (0/10) |
| SCLC | 40% (4/10) | 60% (6/10) | 10% (1/10) | 20% (2/10) | 0% (0/10) |
| LUAD | 0% (0/10) | 40% (4/10) | 20% (2/10) | 20% (2/10) | 100% (10/10) |
The performance of the five models.
| SQ | LUAD | SCLC | |
|---|---|---|---|
| Linear nu-SVC SVM | |||
| Sensitivity | 71.290% | 8.261% | 84.192% |
| Specificity | 51.706% | 92.294% | 87.872% |
| Ppv | 42.465% | 34.895% | 77.633% |
| Npv | 78.270% | 66.800% | 91.747% |
| Linear C-SVC SVM | |||
| Sensitivity | 81.645% | 82.890% | 88.885% |
| Specificity | 90.484% | 91.442% | 94.784% |
| Ppv | 81.096% | 82.885% | 89.495% |
| Npv | 90.791% | 91.445% | 94.461% |
| Linear LDA | |||
| Sensitivity | 70.900% | 20.001% | 50.878% |
| Specificity | 50.469% | 100.000% | 70.420% |
| Ppv | 41.715% | 100.000% | 46.237% |
| Npv | 77.622% | 71.429% | 74.141% |
| Quadratic LDA | |||
| Sensitivity | 91.562% | 23.387% | 68.405% |
| Specificity | 58.896% | 99.398% | 83.382% |
| Ppv | 52.692% | 95.107% | 67.300% |
| Npv | 93.315% | 72.182% | 84.072% |
| Mahalanobis LDA | |||
| Sensitivity | 0.005% | 100.000% | 0.010% |
| Specificity | 100.000% | 0.008% | 100.000% |
| Ppv | 100.000% | 33.335% | 100.000% |
| Npv | 66.668% | 100.000% | 66.669% |